Renalytix Email Format
Biotechnology ResearchNew York, United States51-200 Employees
RenalytixAI is a biotechnology research company focused on kidney health, headquartered at 1460 Broadway, New York, New York. The company describes itself as the founder and global leader in the bioprognosis field for kidney health, developing a proprietary solution that enables early-stage progression risk assessment. Its product portfolio includes the FDA-approved kidneyintelX.dkd test, designed to predict progressive decline in kidney function, particularly in patients with type 2 diabetes and early-stage CKD. RenalytixAI operates in the biotechnology research industry and employs 51 to 200 people. In recent years, the company has pursued partnerships and financing activity, including a 2025 collaboration with Tempus to advance intelligent risk assessment in diabetic kidney disease and a 2026 integration with Carna Health's digital care platform. The company is listed on the London Stock Exchange (RENX) and NASDAQ (RNLX).
1-888-653-2347 
support@leadiq.com 
